KR100309072B1 - Method for sialidase assay - Google Patents
Method for sialidase assay Download PDFInfo
- Publication number
- KR100309072B1 KR100309072B1 KR1019990021332A KR19990021332A KR100309072B1 KR 100309072 B1 KR100309072 B1 KR 100309072B1 KR 1019990021332 A KR1019990021332 A KR 1019990021332A KR 19990021332 A KR19990021332 A KR 19990021332A KR 100309072 B1 KR100309072 B1 KR 100309072B1
- Authority
- KR
- South Korea
- Prior art keywords
- sialidase
- titer
- measuring
- glycoprotein
- present
- Prior art date
Links
- 102000005348 Neuraminidase Human genes 0.000 title claims abstract description 60
- 108010006232 Neuraminidase Proteins 0.000 title claims abstract description 60
- 238000000034 method Methods 0.000 title claims abstract description 38
- 238000003556 assay Methods 0.000 title abstract description 3
- 102000003886 Glycoproteins Human genes 0.000 claims description 18
- 108090000288 Glycoproteins Proteins 0.000 claims description 18
- 239000002523 lectin Substances 0.000 claims description 16
- 102000004190 Enzymes Human genes 0.000 claims description 12
- 108090000790 Enzymes Proteins 0.000 claims description 12
- 102000007365 Sialoglycoproteins Human genes 0.000 claims description 11
- 108010032838 Sialoglycoproteins Proteins 0.000 claims description 11
- 239000000427 antigen Substances 0.000 claims description 8
- 102000036639 antigens Human genes 0.000 claims description 7
- 108091007433 antigens Proteins 0.000 claims description 7
- 229920001542 oligosaccharide Polymers 0.000 claims description 7
- 150000002482 oligosaccharides Chemical class 0.000 claims description 7
- 239000000758 substrate Substances 0.000 claims description 7
- 102000003951 Erythropoietin Human genes 0.000 claims description 6
- 108090000394 Erythropoietin Proteins 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 claims description 4
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 4
- 239000007857 degradation product Substances 0.000 claims description 4
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 claims description 4
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 claims description 4
- 229940105423 erythropoietin Drugs 0.000 claims description 4
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 4
- 241001521402 Maackia <angiosperm> Species 0.000 claims description 2
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 abstract description 21
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 abstract description 21
- 102000004169 proteins and genes Human genes 0.000 abstract description 10
- 108090000623 proteins and genes Proteins 0.000 abstract description 10
- 238000002965 ELISA Methods 0.000 abstract description 9
- 238000006243 chemical reaction Methods 0.000 abstract description 9
- 230000035945 sensitivity Effects 0.000 abstract description 6
- 210000004027 cell Anatomy 0.000 description 21
- 239000000523 sample Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 238000005406 washing Methods 0.000 description 7
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 229940060155 neuac Drugs 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102000004856 Lectins Human genes 0.000 description 3
- 108090001090 Lectins Proteins 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000006225 natural substrate Substances 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 239000003656 tris buffered saline Substances 0.000 description 2
- OGNVQLDIPUXYDH-ZPKKHLQPSA-N (2R,3R,4S)-3-(2-methylpropanoylamino)-4-(4-phenyltriazol-1-yl)-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid Chemical compound CC(C)C(=O)N[C@H]1[C@H]([C@H](O)[C@H](O)CO)OC(C(O)=O)=C[C@@H]1N1N=NC(C=2C=CC=CC=2)=C1 OGNVQLDIPUXYDH-ZPKKHLQPSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101100298998 Caenorhabditis elegans pbs-3 gene Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241001673391 Entandrophragma candollei Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 241001521394 Maackia amurensis Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- SQVRNKJHWKZAKO-LUWBGTNYSA-N N-acetylneuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-LUWBGTNYSA-N 0.000 description 1
- 229920002274 Nalgene Polymers 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 210000000677 aggregate cell Anatomy 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- RIIWUGSYXOBDMC-UHFFFAOYSA-N benzene-1,2-diamine;hydron;dichloride Chemical compound Cl.Cl.NC1=CC=CC=C1N RIIWUGSYXOBDMC-UHFFFAOYSA-N 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000003271 compound fluorescence assay Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 108010042430 galactose receptor Proteins 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- CERZMXAJYMMUDR-UHFFFAOYSA-N neuraminic acid Natural products NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO CERZMXAJYMMUDR-UHFFFAOYSA-N 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- PTLRDCMBXHILCL-UHFFFAOYSA-M sodium arsenite Chemical compound [Na+].[O-][As]=O PTLRDCMBXHILCL-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4724—Lectins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/505—Erythropoietin [EPO]
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
본 발명은 ELISA(Enzyme Linked Immunosorbent assay) 방법을 이용하는 시알리다제(sialidase)의 역가 측정방법(assay)에 관한 것으로서, 간편하면서도 높은 감도를 얻을 수 있을 뿐 아니라, 샘플내에 이미 존재하는 시알산으로 인해 발생하는 위-양성(false-positive)의 가능성을 차단할 수 있고 동일한 플레이트상에서의 반응으로 탁월한 재현성을 가지며, 특히 목표 단백질에 대한 시알리다제의 역가를 직접 측정할 수 있다The present invention relates to an assay for assaying the titer of sialidase using the Enzyme Linked Immunosorbent assay (ELISA) method, which provides a simple and high sensitivity as well as sialic acid already present in the sample. It can block the possibility of false-positives that occur and has excellent reproducibility with reactions on the same plate, and in particular can directly measure the titer of sialidase for the target protein.
Description
본 발명은 목표 단백질에 대한 시알리다제(sialidase)의 역가를 직접 측정하는 방법에 관한 것으로서, 더욱 상세하게는, ELISA(Enzyme Linked Immunosorbent assay) 방법을 이용하여, 목표 단백질로부터 시알리다제에 의해 제거되는 시알산(sialic acid)을 정량하는 방법에 관한 것이다.The present invention relates to a method for directly measuring the titer of sialidase on a target protein, and more particularly, by eliminating sialidase from a target protein using an Enzyme Linked Immunosorbent assay (ELISA) method. It relates to a method for quantifying sialic acid.
시알산은 N-노이라민산(neuraminic acid)의 아민 유도체의 총칭으로서, 뮤코다당, 당단백질, 당지질, 인유의 올리당 등의 구성성분으로 생물계에 광범위하게분포하고 있다. 특히, 고등동물의 당단백질 또는 당지질의 말단에 존재하며 이들의 분자구조에 지대한 영향을 미친다. 이러한 시알산은 세포와 세포 분자간의 상호작용에 있어서 2가지 역할을 담당하는데, 제 1 역할은 세포 또는 분자의 인식부위(recognition determinant)를 차폐(masking)하는 것이고, 제 2 역할은 시알산 자체가 인식부위로 작용하는 것이다.Sialic acid is a generic term for amine derivatives of N-neuraminic acid, and is widely distributed in the biological system as constituents such as mucopolysaccharide, glycoprotein, glycolipid, and oligosaccharide of human oil. In particular, they are present at the ends of glycoproteins or glycolipids of higher animals and have a profound effect on their molecular structure. These sialic acids play two roles in the interaction between cells and cell molecules. The first role is to mask the recognition determinant of the cell or molecule, and the second role is to recognize sialic acid itself. It acts as a site.
중국 햄스터 난소(Chinese Hamster Ovary: CHO) 세포에 존재하는 시알리다제는 다음과 같이 배양액내에 함유되어 있는 시알로(sialo) 당단백질로부터 시알산을 제거한다.Sialidase present in Chinese Hamster Ovary (CHO) cells removes sialic acid from the sialo glycoproteins contained in the culture as follows.
당단백질의 생체내 활성은 시알산의 존재 여부와 밀접한 관계를 갖는 바, 시알산이 제거된 당단백질은 생체내 활성이 급격히 감소된다. 그 이유는 당단백질의 당쇄 말단에 존재하면서 그 다음 당인 갈락토스와 대부분 α-2,3-결합으로 연결되는 시알산이 세포 배양액내에 존재하는 시알리다제에 의해 탈락되면 갈락토스 잔기가 노출되고, 이 아시알로(asialo) 당단백질은 간세포의 갈락토스 수용체에 의해 인식되어 간세포에 포획되어 대사되기 때문이다.The in vivo activity of glycoproteins is closely related to the presence or absence of sialic acid, and thus the glycoprotein from which sialic acid has been removed is rapidly reduced in vivo. The reason is that when sialic acid, which is present at the sugar chain terminal of the glycoprotein and is connected to the next sugar galactose and mostly α-2,3-linked, is eliminated by the sialidase present in the cell culture, the galactose residue is exposed. (Asialo) glycoproteins are recognized by galactose receptors in hepatocytes and captured and metabolized in hepatocytes.
만약 세포에 의해 시알리다제가 생산되지 않는다면 세포 배양액내에 시알리다제가 존재하지 않을 것이며, 배양액내에 함유되어 있는 여러가지 당단백질을 수식하지 않을 것이다. 이 시알리다제가 어느 곳으로부터 유래되는지는 아직까지 불분명한데, 세포 배지에 함유되어 있는 혈청내에 존재하거나, 세포로부터 배출되거나, 세포 원형질액에 함유되어 있는 시알리다제가 세포가 파쇄되면서 유출되는 가능성을 고려해볼 수 있다. Munzert, E. 등(Biotechnol. Prog. 12: 559-563, 1996)의 연구에 의하면, 회분배양 동안 락테이트 디하이드로게나제(lactate dehydrogenase)의 증가와 더불어 시알리다제의 증가가 관찰되었으며, 이로부터 사멸 세포수와 원형질액으로부터의 시알리다제 배출간에 상관관계가 있음을 알 수 있다. 따라서 세포 배양액내의 시알다제는 주로 사멸 세포의 원형질액으로부터 유래되는 것으로 추정된다.If the cells do not produce sialidase, there will be no sialidase present in the cell culture, and it will not modify the various glycoproteins contained in the culture. It is still unclear where this sialidase comes from, taking into account the possibility that sialidase, which is present in the serum contained in the cell medium, released from the cell, or contained in the cell protoplasts, leaks as the cell breaks down. You can try A study by Munzert, E. et al. (Biotechnol. Prog. 12: 559-563, 1996) observed an increase in sialidase with an increase in lactate dehydrogenase during batch culture. There is a correlation between dead cell numbers and sialidase release from the plasma solution. Thus, sialidase in cell culture is presumed to be derived mainly from the plasma solution of dead cells.
CHO 세포의 시알리다제는 1993년에 Warner T.G. 등(Glycobiology 3: 455-463, 1993)에 의해 정제되었다. 정제된 시알리다제의 분자량은 43,000돌턴에 달하고 등전점은 pH 6.8 내지 7.0 사이로 나타났다. 시알리다제의 최적 pH는 5.9이고 2,3-결합에 대한 역가가 2,6-결합에 비하여 4배 정도 강하게 나타났다. Ferrari, J. 등은 1994년에 cDNA를 클로닝하였으며, 379개의 아미노산으로 구성된 단백질이 예상되었고 이 단백질은 여러가지의 박테리아 시알리다제와 서열 유사성을 나타내었다.Sialidase of CHO cells was established in 1993 by Warner T.G. Purified by Glycobiology 3: 455-463, 1993. The molecular weight of the purified sialidase reached 43,000 Daltons and the isoelectric point was found to be between pH 6.8 and 7.0. The optimal pH of sialidase was 5.9 and the titer for 2,3-bond was about four times stronger than 2,6-bond. Ferrari, J. et al. Cloned cDNA in 1994 and expected a protein consisting of 379 amino acids, which showed sequence similarity with various bacterial sialidases.
현재까지 알려진 시알리다제의 역가 측정방법으로는 다음의 2가지 방법이 있다.There are two methods for measuring the titer of sialidase known to date.
첫째, 형광 역가 측정방법(fluorescent assay)(Potier et al., Anal. Biochem. 94, 287, 1979)은 형광물질이 부착된 시알산 유사체, 즉 4-MU-NeuAC((4-methylumbelliferyl-5-acetamido-3,5-dideoxy-D-glycero-a-D-galacto-nonulopyanosid)onic acid)를 기질로 사용하는 방법으로, 시알리다제에 의해 움벨리페론(umbelliferone)이 유리되면 그로부터의 형광 강도를 측정함으로써 시알리다제 역가를 측정하게 된다. 이 방법은 감도가 우수하다는 장점을 갖지만, 여러가지 단점을 갖는다. 즉 여러가지 설비(예를 들어, HPLC, 플루오로미터(fluorometer), 오토샘플러(autosampler)) 등이 필요하고, 실험자들이 설비에 대해 고도로 숙련되어야 하며, 생성된 플루오로포어(fluorophore)가 시간에 따라 불안정하다는 단점을 갖는다. 또한 기질 유사체를 사용함으로 인하여 실제의 효소 특이성이 천연 기질과 다를 수 있는 가능성도 배제할 수 없다.First, the fluorescence assay (Potier et al., Anal. Biochem. 94, 287, 1979) is a sialic acid analog to which a fluorescent substance is attached, namely 4-MU-NeuAC ((4-methylumbelliferyl-5- acetamido-3,5-dideoxy-D-glycero-aD-galacto-nonulopyanosid) onic acid) is used as a substrate.When umbelliferone is released by sialidase, the fluorescence intensity therefrom is measured. Sialidase titers will be measured. This method has the advantage of excellent sensitivity, but has various disadvantages. That is, various equipment (e.g. HPLC, fluorometer, autosampler), etc. are required, the experimenters must be highly skilled with the equipment, and the resulting fluorophore is It has the disadvantage of being unstable. In addition, the use of substrate analogs does not exclude the possibility that the actual enzyme specificity may differ from the natural substrate.
둘째, TBA 역가 측정방법(thiobabituric acid assay)(Uchida et al., J. Biochem., 82, 1425∼1433, 1977)은 천연 기질을 사용하는 방법으로, 시알로 올리고당과 같은 물질에 시알리다제를 직접 가하여 유리되는 시알산을 티오바비튜레이트(thiobabiturate)를 이용하여 정량하는 방법이다. 이 방법은 유리 시알산을 검출하는 고전적인 방법으로, 샘플을 측정하기 전에 여러가지 전처리를 하여야 하는 번거로움이 따른다. 또한 샘플내에 이미 존재하는 시알산이 함께 검출되므로 시알리다제 역가가 실제 보다 높게 나타날 위험이 있다.Second, the TBA titer (thiobabituric acid assay) (Uchida et al., J. Biochem., 82, 1425-1433, 1977) is a method of using a natural substrate, which allows sialidase to be applied to substances such as sialo oligosaccharides. It is a method of quantifying sialic acid which is directly added and liberated by thiobabiturate. This method is a classical method of detecting free sialic acid, which is cumbersome to require various pretreatments before measuring the sample. In addition, there is a risk that the sialidase titer will be higher than it is because sialic acid already present in the sample is detected together.
한편, ELISA는 특정한 항체 또는 항원에 대한 고감도의, 공지된 면역측정방법(immunoassay)이다. 예를 들면, 특정 항체의 활성을 측정하기 위해서는, 항혈청(또는 기타 시료)을 플라스틱 튜브 등의 내면에 흡착된 균질한 항원과 반응시킨 후 결합되지 않은 항체를 세척하여 제거한다. 이어서, 고정화된 항원에 결합된 항체를 각각 특정 타입의 효소와 공유결합된 항-면역글로불린(immunoglobulin)항체로 이루어진 컨쥬게이트(conjugate)로 처리한 후, 결합되지 않은 컨쥬게이트를 세척하여 제거하고, 적합한 기질과 함께 배양하여 효소 분해산물을 측정한다. 한편, 특정 항원의 활성을 측정하기 위해서는, 항체를 흡착시키고 효소를 항-항원 항체에 컨쥬게이트시키는 것을 제외하고는 상기 방법과 동일한 방법을 이용할 수 있다.ELISA, on the other hand, is a high sensitivity, known immunoassay for specific antibodies or antigens. For example, to measure the activity of a particular antibody, the antiserum (or other sample) is reacted with a homogenous antigen adsorbed on the inner surface of a plastic tube or the like, followed by washing off the unbound antibody. The antibody bound to the immobilized antigen is then treated with a conjugate of anti-immunoglobulin antibodies, each covalently bound to a specific type of enzyme, followed by washing off the unbound conjugate, Incubate with a suitable substrate to determine enzyme degradation products. On the other hand, in order to measure the activity of a specific antigen, the same method as the above method can be used except that the antibody is adsorbed and the enzyme is conjugated to the anti-antigen antibody.
그러나, 본 발명에서와 같이 ELISA 방법을 시알로 당단백질을 검출하는데 이용하려는 시도는 현재까지 전혀 이루어진 바 없었다.However, no attempt has been made to use the ELISA method to detect glycoproteins in sial as in the present invention.
이에 본 발명자들은 상기한 바와 같은 문제점을 해결할 수 있는 신규한 시알리다제의 역가 측정방법을 개발하기 위하여 지속적인 연구를 수행한 결과, 본 발명에서와 같이 공지의 ELISA 방법을 이용하면 간편하면서도 높은 감도를 얻을 수 있을 뿐 아니라, 샘플내에 이미 존재하는 시알산으로 인해 발생하는 위-양성(false-positive)의 가능성을 차단할 수 있고 동일한 플레이트(plate)상에서의 반응으로 탁월한 재현성을 가지며, 특히 목표 단백질에 대한 시알리다제의 역가를 직접 측정할 수 있음을 발견하고, 본 발명을 완성하기에 이르렀다.Accordingly, the present inventors have conducted continuous research to develop a novel method for measuring the titer of sialidase, which can solve the problems described above. As a result, the present invention provides a simple and high sensitivity. Not only can it be obtained, it can block the possibility of false-positive caused by sialic acid already present in the sample and has excellent reproducibility by reaction on the same plate, especially for the target protein. It has been found that the titer of sialidase can be measured directly and the present invention has been completed.
따라서, 본 발명의 목적은 간편하면서도 높은 감도를 얻을 수 있으며, 샘플내에 이미 존재하는 시알산으로 인해 발생하는 위-양성의 가능성을 차단할 수 있고 동일한 플레이트상에서의 반응으로 탁월한 재현성을 가지며, 특히 목표 단백질에 대한 시알리다제의 역가를 직접 측정할 수 있는, 신규한 시알리다제의 역가 측정방법을 제공하기 위한 것이다.Thus, the object of the present invention is to achieve a simple yet high sensitivity, to block the possibility of gastric-positive events caused by sialic acid already present in the sample and to have excellent reproducibility with reactions on the same plate, in particular the target protein. It is to provide a novel method for measuring the titer of sialidase, which can directly measure the titer of sialidase.
도 1은 본 발명에 따른 역가 측정방법의 원리를 나타내는 모식도:1 is a schematic diagram showing the principle of the titer measuring method according to the present invention:
도 2는 4-MU-NeuAc 역가 측정방법을 사용하여 얻은 시알리다제 역가의 표준곡선을 나타내는 그래프;2 is a graph showing a standard curve of sialidase titer obtained using the 4-MU-NeuAc titer method;
도 3은 본 발명에 따른 역가 측정방법을 사용하여 얻은 시알리다제 역가의 표준곡선을 나타내는 그래프; 및3 is a graph showing a standard curve of sialidase titer obtained using the titer measuring method according to the present invention; And
도 4는 본 발명에 따른 역가 측정방법을 사용하여 세포배양중 시알리다제 역가변화를 측정한 결과를 나타내는 그래프.Figure 4 is a graph showing the results of measuring the change in sialidase titer in cell culture using the method for measuring titers according to the present invention.
상기한 바와 같은 목적을 달성하기 위하여, 본 발명은 ELISA 방법을 이용하는 것을 특징으로 하는 시알리다제의 역가 측정방법을 제공한다. 본 발명의 방법은 시알리다제로 처리된 시알로 당단백질(항원)에 시알로 올리고당을 특이적으로 인식하는 물질(항체)을 가하여 시알로 당단백질을 검출하는 것을 특징으로 한다. 본 발명에 있어서, 시알로 올리고당을 특이적으로 인식하는 물질은 MAA-렉틴(MAA-Lectin; Maackia amurensis-Lectin)인 것이 바람직하다. 본 발명의 일례에서 MAA-렉틴은 디곡시게닌(digoxygenin)과 결합된 것이며, 이 경우 효소와 컨쥬게이트(conjugate)된 항-디곡시게닌 항체로 처리한 후, 기질을 가하여 효소 분해산물을 측정함으로써 시알로 당단백질을 검출할 수 있다.In order to achieve the object as described above, the present invention provides a method for measuring the titer of sialidase, characterized by using the ELISA method. The method of the present invention is characterized by detecting a sial glycoprotein by adding a sial oligosaccharide-specific substance (antibody) to a sial glycoprotein (antigen) treated with sialidase. In the present invention, the substance that specifically recognizes the sally oligosaccharide is preferably MAA-Lectin (Maackia amurensis-Lectin). In one example of the present invention, MAA-lectin is bound to digoxigenin, and in this case, by treatment with an anti-digoxigenin antibody conjugated with an enzyme, a substrate is added to measure the enzyme degradation product. Sial can detect glycoproteins.
본 발명의 방법에 따르면, 시알로 당단백질은 플레이트상에 고정되는 것이 바람직하다. 또한 본 발명의 일례에 따르면, 시알로 당단백질은 에리스로포이에틴(erythropoietin, EPO)이며, 시알리다제는 CHO 세포로부터 유래되는 것일 수 있다.According to the method of the invention, the sialo glycoprotein is preferably immobilized on the plate. According to one embodiment of the present invention, the sialo glycoprotein is erythropoietin (EPO), and the sialidase may be derived from CHO cells.
이하, 본 발명을 더욱 상세히 설명한다.Hereinafter, the present invention will be described in more detail.
본 발명은 시알로 당단백질에 작용하는 시알리다제의 역가를 직접 측정하는 방법에 관한 것이다. 본 발명의 바람직한 일례에서, 시알로 당단백질(예를 들면, 에리스로포이에틴)에 대한 항체가 흡착되어 있는 플레이트상에, 시알로 당단백질(항원)을 고정시킨 후, 일정시간 동안 시알리다제로 처리하고, 시알리다제를 세척하여 제거한다. 여기에 시알로 올리고당만을 선택적으로 인식하는 MAA-렉틴(항체)을가한다. MAA-렉틴은 'Maackia amurensis'라 불리우는 콩과목(legume tree)으로부터 분리된 렉틴이다. 렉틴은 적혈구 및 많은 다른 타입의 세포를 응집시킬 수 있는 자연계에 널리 분포되어 있는 일군의 단백질로서, 그 존재는 Stillmark가 피마자 열매로부터 헤마글루티닌(hemagglutinin)을 분리해낸 1899년부터 알려져 있었으나, 렉틴이라는 용어는 W.C. Boyd 등(Science 119, 419, 1954)에 의해 최초로 소개되었다. 현재 렉틴은 '세포를 응집시키고/거나 당컨쥬게이트(glycoconjugate)를 침전시키는 비-면역 유래의 당-결합 단백질 또는 당단백질'을 의미하는 것으로 사용되고 있다. 따라서, MAA-렉틴은 시알산을 함유하는 당컨쥬게이트에 대해 특이성을 갖는다.The present invention relates to a method for directly measuring the titer of sialidase acting on sialo glycoproteins. In a preferred embodiment of the present invention, the sialo glycoprotein (antigen) is immobilized on a plate to which an antibody against sialo glycoprotein (for example, erythropoietin) is adsorbed, and then treated with sialidase for a predetermined time, Remove sialidase by washing out. To this is added MAA-lectin (antibody) which selectively recognizes only sialo oligosaccharides. MAA-lectins are lectins isolated from the legume tree called 'Maackia amurensis'. Lectin is a group of proteins widely distributed in the natural world that can aggregate red blood cells and many other types of cells, the existence of which was known since 1899 when Stillmark isolated hemagglutinin from castor fruit. The term WC First introduced by Boyd et al. (Science 119, 419, 1954). Lectins are currently used to mean 'non-immune sugar-binding proteins or glycoproteins that aggregate cells and / or precipitate glycoconjugates'. Thus, MAA-lectins have specificity for sugar conjugates containing sialic acid.
본 발명에서는, MAA-렉틴을 디곡시게닌과 결합시킨 'MAA-렉틴-디곡시게닌'을 시알리다제로 처리된 시알로 당단백질에 가한 후, 결합되지 않은 MAA-렉틴-디곡시게닌을 세척하여 제거한다. 여기에 디곡시게닌에 대한 항체를 퍼옥시다제와 같은 특정 타입의 효소에 공유결합시킨 '항-디곡시게닌 항체-효소 컨쥬게이트'를 가하고, 결합되지 않은 컨쥬게이트를 세척하여 제거한다. 적합한 기질을 가하고 발색반응 등의 방법을 사용하여 효소 분해산물을 측정함으로써, 시알리다제로 처리한 후의 시알로 당단백질을 검출할 수 있게 된다. 시알리다제는 시알로 당단백질로부터 시알산을 제거하므로, MAA-렉틴의 결합량은 시알리다제 처리전 보다 감소할 것이며, 따라서 시알리다제 처리 전 보다 낮은 정도의 발색반응을 나타낼 것이다. 이로부터 시알로 당단백질에 대한 시알리다제의 역가를 직접 측정할 수 있게 된다. 즉, MAA-렉틴의 결합량이 감소하고 이에 따라 발색반응이 감소할수록, 시알리다제의 역가는 높은 것을 의미한다.In the present invention, 'MAA-lectin-digoxigenin', which binds MAA-lectin with digoxigenin, is added to sialo glycoproteins treated with sialidase, followed by washing unbound MAA-lectin-digoxigenin. Remove To this is added an 'anti-digoxigenin antibody-enzyme conjugate' in which an antibody against digoxigenin is covalently bound to a specific type of enzyme such as peroxidase, and the unbound conjugate is washed off. By adding an appropriate substrate and measuring the enzymatic degradation product using a method such as color reaction, the glycoprotein can be detected by sial after treatment with sialidase. Since sialidase removes sialic acid from sialo glycoproteins, the amount of binding of MAA-lectin will be lower than before sialidase treatment, thus resulting in a lower degree of color reaction than before sialidase treatment. From this it is possible to directly measure the titer of sialidase on sialo glycoprotein. That is, as the binding amount of MAA-lectin decreases and thus the color reaction decreases, the titer of sialidase is higher.
[실시예]EXAMPLE
이하, 본 발명을 실시예에 의거 보다 상세히 설명하고자 하나, 이는 본 발명의 이해를 돕기 위한 것일 뿐, 본 발명의 범위를 어떤 식으로든지 제한하고자 하는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to Examples, which are only intended to help the understanding of the present invention, and are not intended to limit the scope of the present invention in any way.
[제조예 1] 시알리다제 원액의 제조Preparation Example 1 Preparation of Sialidase Stock Solution
CHO 세포를 37℃에서 5%의 CO2가 공급되는 T-플라스크(Nalgene)에서 성장시켰다. 배지는 DMEM/F12로서 2mM 글루타민(Gibco), 5% 우태아혈청(Fetal bovine serum)(Hyclone), 항생제(100U/㎖ 페니실린 G, 100μg/㎖ 스트렙토마이신, 25μg/㎖ 앰포테리신(amphotericin) B)가 첨가되었다.CHO cells were grown in T-flask (Nalgene) fed 5% CO 2 at 37 ° C. Medium was DMEM / F12 with 2 mM glutamine (Gibco), 5% Fetal bovine serum (Hyclone), antibiotic (100 U / ml penicillin G, 100 μg / ml streptomycin, 25 μg / ml amphotericin B) ) Was added.
효소 역가 측정을 위하여, 배지에서 컨플루언트(confluent) 상태로 자란 세포(5x105cell/cm2)를 트립신으로 처리하고, 1:4의 비율로 100mm 조직 배양 디쉬로 계대하였다. 1~2일 후에 세포를 얻어 10㎖의 냉 PBS(Phosphate buffered saline: 8g/ℓ NaCl, 0.2g/ℓ KCl, 1.13g/ℓ Na2HPO4및 0.2g/ℓ KH2PO4, pH 7.5)로 2회 세척하였다. 3회차 PBS 10㎖을 부어 넣고 10분간 4℃에서 방치하여 세포가 느슨해지게 하였다. 이 세포를 모아서 원심분리관에 가하고 일부는 세포 계수하였다. 나머지 세포들은 100×g에서 10분간 원심분리하였다. PBS를 제거한후 세포들을 냉수에 가하여 1×107세포/㎖(3.3mg/㎖)가 되도록 현탁시켰다. 22 게이지 바늘을 5회 통과시켜 세포를 완전 파쇄하였다.For enzyme titer determination, cells grown confluent in the medium ( 5 × 10 5 cells / cm 2 ) were treated with trypsin and passaged with 100 mm tissue culture dishes at a ratio of 1: 4. After 1-2 days, cells were obtained and 10 ml of cold PBS (Phosphate buffered saline: 8 g / l NaCl, 0.2 g / l KCl, 1.13 g / l Na 2 HPO 4 and 0.2 g / l KH 2 PO 4 , pH 7.5) Washed twice. Pour 10ml of PBS 3 times and left for 10 minutes at 4 ℃ to loosen the cells. The cells were collected and added to a centrifuge tube and some cells were counted. The remaining cells were centrifuged at 100 x g for 10 minutes. After removing PBS, the cells were added to cold water and suspended to 1 × 10 7 cells / ml (3.3 mg / ml). Cells were completely disrupted by five passes through a 22 gauge needle.
[실시예 1] ELISA 방법을 이용한 시알리다제의 역가 측정Example 1 Measurement of Titer of Sialidase Using ELISA Method
당단백질에 결합되어 있는 시알산에 대한 시알리다제의 영향을 알아보기 위하여, 목표 단백질을 인식하는 단클론 항체를 마이크로타이터 플레이트(microtiter plate)(Maxisorp; Nunc, Wiesbaden, Germany)에 흡착시키고, 그 위에 다시 목표단백질을 결합시킨 후 시알리다제로 처리하였다. 시알리다제는 당단백질에 결합되어 있는 시알산을 제거하므로 시알산을 인식하는 MAA-렉틴의 결합 정도는 감소하게 되며 이후에 수행되는 발색반응에서 시알리다제로 처리되지 않은 대조군에 비해 낮은 발색반응을 나타낼 것으로 예상되었다.To determine the effect of sialidase on sialic acid bound to glycoproteins, monoclonal antibodies that recognize the target protein were adsorbed onto a microtiter plate (Maxisorp; Nunc, Wiesbaden, Germany), and The target protein was bound to the stomach again and treated with sialidase. Since sialidase removes sialic acid bound to glycoproteins, the degree of binding of sialic acid-recognized MAA-lectins is reduced, and subsequent color development lowers the color development compared to controls not treated with sialidase. It was expected to show.
시알로 당단백질인 EPO에 대한 단클론 항체인 CFC-6를 2.5μg/㎖의 농도로 100 ㎕씩 분주하여 96-웰 마이크로타이터 플레이트에 가하고 37℃에서 1∼2시간 동안 반응시켰다. 블록킹 용액(0.5% 젤라틴의 단백질가수분해 분해산물)을 가하고 실온에서 1시간 동안 블록킹시켰다. PBST(0.01M 인산 완충액, 0.0027M 염화칼륨, 0.137M 염화나트륨, pH 7.4, 0.05% 트윈 20)로 4회 세척하였다. 목표 단백질 EPO를 100㎕씩 각 웰에 가하고 37℃에서 1시간 동안 반응시켰다(대조군). PBST로 다시 4회 세척한 후 제조예 1에서 얻은 효소원액을 일정 비율로 희석하여 첨가한 후 다시 37℃에서 1시간 동안 반응시켰다. PBST로 4회 세척한 후 MAA-렉틴-디곡시게닌 용액(1 mg/㎖)을 TBS(Tris buffered saline, 50mM Tris-HCl, 150mM NaCl, pH 7.5, 1mM MgCl2, 1mM MnCl2, 1mM CaCl2)로 1,000배 희석하여 100㎕씩 가한 후, 실온에서 1시간 동안 반응시켰다. PBST 세척 후 퍼옥시다제 컨쥬게이트된 항-디곡시게닌 다클론 항체를 TBS로 2,000배 희석하여 100㎕씩 가하고 37℃에서 1시간 동안 반응시켰다. 기질 완충액(0.1M 시트르산, 0.1M 인산나트륨, pH 5.0) 20㎖에 O-페닐렌 디아민 디하이드로클로라이드(O-Phenylene diamine dihydrochloride) 20mg을 용해시킨 후 25% H2O230㎕를 첨가하여 용액을 제조하여 각 웰에 100㎕씩 첨가하여 발색시켰다. ELISA 오토리더(autoreader)를 사용하여 OD492에서 수치를 읽은 후 표준곡선(도 3)에 대입하여 시알리다제 역가를 결정하였다(도 4).100 μl of CFC-6, a monoclonal antibody against sipo glycoprotein EPO, was added at a concentration of 2.5 μg / ml, added to a 96-well microtiter plate, and reacted at 37 ° C. for 1-2 hours. Blocking solution (0.5% gelatin hydrolyzate) was added and blocked for 1 hour at room temperature. Washed four times with PBST (0.01 M phosphate buffer, 0.0027 M potassium chloride, 0.137 M sodium chloride, pH 7.4, 0.05% Tween 20). 100 μl of the target protein EPO was added to each well and allowed to react at 37 ° C. for 1 hour (control). After washing four times with PBST again, the enzyme stock solution obtained in Preparation Example 1 was diluted and added at a predetermined rate, and then reacted at 37 ° C. for 1 hour. After washing four times with PBST, MAA-lectin-digoxigenin solution (1 mg / ml) was added to Tris buffered saline, 50 mM Tris-HCl, 150 mM NaCl, pH 7.5, 1 mM MgCl 2 , 1 mM MnCl 2 , 1 mM CaCl 2 ) Was diluted 1,000-fold and added to 100 µl, followed by reaction at room temperature for 1 hour. After washing with PBST, peroxidase conjugated anti-digoxigenin polyclonal antibody was diluted 2,000-fold with TBS, and added to 100 µl and reacted at 37 ° C for 1 hour. Dissolve 20 mg of O-Phenylene diamine dihydrochloride in 20 ml of substrate buffer (0.1 M citric acid, 0.1 M sodium phosphate, pH 5.0) and add 30 μl of 25% H 2 O 2 to the solution. 100 μl was added to each well and developed. Sialidase titers were determined by reading the values from OD 492 using an ELISA autoreader and substituting them into the standard curve (FIG. 3) (FIG. 4).
[비교예 1] 형광 역가 측정방법(4-MU-NeuAc 역가 측정방법)[Comparative Example 1] Fluorescence titer measuring method (4-MU-NeuAc titer measuring method)
시알리다제의 역가를 측정하기 위하여 4-MU-NeuAc 역가 측정방법을 이용하였다(Potier et al., Anal. Biochem. 94, 287, 1979). 이때, 측정 용액의 조성은 다음과 같았다.To determine the titer of sialidase, 4-MU-NeuAc titer was used (Potier et al., Anal. Biochem. 94, 287, 1979). At this time, the composition of the measurement solution was as follows.
0.1M 나트륨 아세테이트(pH 3∼6) 또는 인산칼륨(pH 6∼8) 완충액(10㎕의 1 M 스탁), 1mM 4MU NeuAc(4 mM aliquot로부터 25㎕), 효소시료 25㎕를 합쳐 최종 100㎕로 만들었다. 100㎕의 샘플을 1.5㎖ 시험관에 가하고 37℃ 수조에서 진탕하면서 30분간 반응시켰다. 반응을 0.2M 글리신(pH 10.4) 0.9㎖을 가하여 중지시켰다. 샘플을 12,000×g에서 15분간 원심분리하여 침전물을 제거하고 HPLC 샘플병에서 10배 희석하였다(50㎕ 샘플+450㎕ 글리신 완충액).100 μl final 0.1 M sodium acetate (pH 3-6) or potassium phosphate (pH 6-8) buffer (10 μl 1 M stock), 1 mM 4MU NeuAc (25 μl from 4 mM aliquot), 25 μl enzyme sample Made with. 100 μl of sample was added to a 1.5 ml test tube and allowed to react for 30 minutes while shaking in a 37 ° C. water bath. The reaction was stopped by adding 0.9 ml of 0.2 M glycine (pH 10.4). Samples were centrifuged at 12,000 × g for 15 minutes to remove precipitate and diluted 10-fold in HPLC sample bottles (50 μl sample + 450 μl glycine buffer).
형광 검출기가 부착된 HPLC에서 오토샘플 인젝터를 사용하여 측정하였다. 이때, 소멸파장은 365nm, 발산파장은 448nm를 각각 사용하였다.Measurements were made using an autosample injector on HPLC with fluorescence detector. At this time, the extinction wavelength was 365nm, the diverging wavelength was used 448nm.
[비교예 2] TBA 역가 측정방법Comparative Example 2 Method for Measuring TBA Titer
샘플용액과 표준용액(0.5㎖의 물에 3∼30μg의 시알산 함유)에 0.25㎖의 퍼요오데이트 용액(0.125N H2SO4내 0.025M 퍼요오드산)을 가하여 30분간 37℃에서 방치시켜 산화시켰다. 과량의 퍼요오드산을 0.2㎖의 나트륨 아세나이트(sodium arsenite) 용액을 사용하여 환원시켰다. 유리된 요오드의 황색이 사라지는 즉시, 2㎖의 티오바비튜레이트 용액(0.1M, pH 9.0)을 가하고 샘플에 마개를 씌운 후 끓는 물에서 7.5분 동안 중탕하였다. 발색된 용액을 빙수속에서 냉각시킨 후 4㎖의 산-부탄올 용액(n-부탄올 함유 5%(v/v) 12N HCl)을 가하고 흔들어 주었다. 부탄올층과 수층을 분리한 후, 부탄올층을 취하여 549nm에서 색의 강도를 측정하였다. 시알산의 몰 흡광도는 70,700이었다.To a sample solution and a standard solution (containing 0.5-30 ml of sialic acid in 0.5 ml of water), 0.25 ml of periodate solution (0.025 M periodic acid in 0.125NH 2 SO 4 ) was added and left at 37 ° C for 30 minutes for oxidation. I was. Excess periodic acid was reduced using 0.2 ml of sodium arsenite solution. As soon as the yellow color of the free iodine disappeared, 2 ml of thiobarbiturate solution (0.1M, pH 9.0) was added and the sample was capped and then bathed in boiling water for 7.5 minutes. The colored solution was cooled in ice water, and 4 ml of acid-butanol solution (5% (v / v) 12N HCl containing n-butanol) was added thereto and shaken. After the butanol layer and the aqueous layer were separated, the butanol layer was taken and the intensity of the color was measured at 549 nm. The molar absorbance of sialic acid was 70,700.
본 발명에 따른 시알리다제의 역가 측정방법은 간편하면서도 높은 감도를 얻을 수 있을 뿐 아니라, 샘플내에 이미 존재하는 시알산으로 인해 발생하는 위-양성의 가능성을 차단할 수 있고 동일한 플레이트상에서의 반응으로 탁월한 재현성을 가지며, 특히 목표 단백질에 대한 시알리다제의 역가를 직접 검출할 수 있다.The method for measuring the titer of sialidase according to the present invention is not only easy to obtain high sensitivity, but also blocks the possibility of gastric-positivity caused by sialic acid already present in the sample and is excellent in reaction on the same plate. It is reproducible and in particular can directly detect the titer of sialidase for the target protein.
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019990021332A KR100309072B1 (en) | 1999-06-09 | 1999-06-09 | Method for sialidase assay |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019990021332A KR100309072B1 (en) | 1999-06-09 | 1999-06-09 | Method for sialidase assay |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20010001850A KR20010001850A (en) | 2001-01-05 |
KR100309072B1 true KR100309072B1 (en) | 2001-09-29 |
Family
ID=19591035
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019990021332A KR100309072B1 (en) | 1999-06-09 | 1999-06-09 | Method for sialidase assay |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100309072B1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6574487B1 (en) * | 2000-02-23 | 2003-06-03 | Motorola, Inc. | Communication device with a dual-sided liquid crystal display |
-
1999
- 1999-06-09 KR KR1019990021332A patent/KR100309072B1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
KR20010001850A (en) | 2001-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0291856B1 (en) | A method of determining the presence of endotoxin in a sample | |
Gabius et al. | Lectin localization in human nerve by biochemically defined lectin-binding glycoproteins, neoglycoprotein and lectin-specific antibody | |
US4578361A (en) | Creatinine antibody | |
US7893253B2 (en) | Solid-phase oligosaccharide tagging: a technique for manipulation of immobilized carbohydrates | |
CA2008360A1 (en) | Myocardial infarction immunoassay | |
BRPI0612217A2 (en) | Diagnostic kit for simultaneous measurement of antibiotics from different classes, Diagnostic kit for simultaneous measurement of analytes corresponding to antibiotics of different classes, Diagnostic kit for simultaneous measurement of (beta) -lactams, tetracyclines and sulfamides and method to implement the diagnosis | |
JP2517187B2 (en) | Analyte variant analysis | |
WO1998015646A1 (en) | Chronic fatigue syndrome diagnosis | |
KR100309072B1 (en) | Method for sialidase assay | |
EP0497613B1 (en) | Determination of high molecular weight analytes | |
JP3698563B2 (en) | Method and kit for measuring glycosaminoglycan | |
JPH02216055A (en) | Detection of compound containing carbohydrate | |
CN114720691B (en) | Kit for detecting biomarkers and preparation method and application thereof | |
US6514716B1 (en) | Detection of the end-position sialic acid groups of the human transferrin molecule | |
EP0864863A2 (en) | Use of Anti-Creatinine-Antibodies or other Creatinine bonding substances for the determination of Creatinine in biological samples and method of producing thereof | |
JPWO2017131022A1 (en) | Glycoprotein detection method | |
EP0398292B1 (en) | Diagnostic composition for rheumatoid arthritis | |
KR101054672B1 (en) | Method for analyzing sugar chain terminal sialic acid content of recombinant glycoprotein | |
Bandyopadhyay et al. | Identification of 9-O-acetylated sialoglycans on peripheral blood mononuclear cells in Indian visceral leishmaniasis | |
Zola et al. | Analysis of chemical and biochemical properties of membrane molecules in situ by analytical flow cytometry with monoclonal antibodies | |
Dill et al. | Detection of human asialo-α 1-acid glycoprotein using a heterosandwich immunoassay in conjunction with the light addressable potentiometric sensor | |
AU735205B2 (en) | Vaccine and assay | |
US20200088721A1 (en) | Glycoprotein assay method | |
Huo et al. | Sialic Acids Content Analysis of the Innovator and Biosimilar Darbepoetin Alfa by Fluorometric HPLC Assay | |
JP4251485B2 (en) | Glycolipid measurement method, disease detection method and kit |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130627 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20140603 Year of fee payment: 14 |
|
LAPS | Lapse due to unpaid annual fee |